10 t

with the disease

Claim 1; SEQ ID NO 1369; 180pp; English.

CC This invention relates to novel mitochondrial targets that can be used CC for therapeutic intervention in treating a disease associated with CC altered mitochondrial function. Specifically, it refers to a method for CC identifying proteins of the human heart mitochondrial proteome that are CC useful for drug screening assays, as well as therapeutic targets. The present invention describes a method for identifying such proteins that CC can be used in the treatment of various diseases associated with altered CC mitochondrial function including diabetes mellitus, Huntington's disease, CC catevarthritis, Leber's hereditary optic neuropathy (LHON), mitochondrial CC encephalopathy lactic acidosis and stroke (MELAS), myoclonic epilepsy CC ragged red fibre syndrome (MERRF) or cancer. Accordingly, these CC compositions have neuroprotective, nootropic, antidiabetic, antiarthritic, osteopathic, ophthalmological and CC cytostatic activities. This polypeptide sequence is a human heart control of the invention.

Sequence 401 ₿

Matches Query Match Best Local (52; Similarity Conservative 100.0%; Score 251; DB 7; 100.0%; Pred. No. 7.9e-21; tive 0; Mismatches 0; Length 401; Indels °, 0

GVKETPQQKYQRLLHEVQELTTEVEKIKTTVKESATEEKLTPVLLAKQLAAL 52 GVKBTPQQKYQRLLHEVQELTTEVEKIKTTVKESATEEKLTPVLLAKQLAAL 145

RESULT 4 ABP53018

묽 δ

94

ш

ABP53018 standard; protein; 406 AA.

05-NOV-2002 (first entry)

Human p50 amino acid sequence SEQ ID NO:53.

Cellular proliferation inhibition; cytostatic; antiinflammatory; cancer; p50 inhibitor; dynamitin inhibitor; gene therapy; tumour; carcinoma; psicoma; glioblatoma; leukaemia; lymphoid malignancy; neuronal disorder; sarcoma; glioliar disorder; hypothalamic disorder; inflammatory; glandular disorder; macrophagal stromal disorder; blastocoelic d immunologic disorder. disorder; disorder; epithelial disorder;

Homo sapiens

WO200264779-A2

21-JAN-2002; 2002WO-US001708

14-FEB-2001; 2001US-00782816

) UNIV CALIFORNIA

Ę, Rogers GC, Scholey ž

WPI; 2002-657599/70.

New peptide inhibitors of p50/dynamitin useful for treating cancer by inhibiting cellular proliferation, e.g. benign or malignant tumors, leukemia and lymphoid malignancies, or inflammatory, angiogenic and immunologic disorders.

Disclosure; Fig 1; 55pp; English

The present invention describes an isolated peptide (I) comprising 얹

construction overland, controlled the prostate, pancreatic, lung, vulval, cas necrophagal, epithelial, astrocytal, hypothalamic and other glandular, crepresents human p50 which is given in the present sequence confidence of the matter, and antiinflammatory activities and can be used as p50/dynamitin inhibitors and in gene therapy. The constitution can be used as p50/dynamitin inhibitors and in gene therapy. The constitution of the present invention considered the periods from the present invention consideration, such considered the properties of the prostate, breast, considered the prostate, brother disorders and considered the prostate pancreatic, lung, vulval, considered the prostate pancreatic, lung, vulval, considered the prostate pancreatic as recurrently glial, astrocytal, hypothalamic and other glandular, confidered the presents human p50 which is given in the exemplification of the present through the present and the present sequence of the present through the pre

Sequence 406 AA;

Query Match Best Local Matches Local 52; Similarity GVKETPQQKYQRLLHEVQELTTEVEKIKTTVKESATEEKLTPVLLAKQLAAL Conservative 100.0%; 0 Score 251; DB 5; Pred. No. 8.1e-21; ; Mismatches 0; Length 406; Indels 0 52 Gaps

0,

RESULT 5

片 Ś

99

GVKETPQQKYQRLLHEVQELTTEVEKIKTTVKESATEEKLTPVLLAKQLAAL 150

AAB58968 standard; protein; 465

27-MAR-2001 (first

Breast and ovarian cancer associated antigen protein sequence SEQ ID 676.

antidiabetic; antiinflammatory; antiulcer; vulnerary; anticonvulsant; antibacterial; antifungal; antiparasitic; cardiant; immune disorder; Addison's disease; allergy; autoimmune haemolytic anaemia; autoimmune thyroiditis; diabetes mellitus; Crohn's disease; cardiovascular Human; breast cancer; ovarian cancer; multiple sclerosis; rheumatoid nootropic; neurpprotective; antiviral; antiallergic; hepatotropic; disorder; arthritis; ulcerative colitis; healing; neurological disease. cytostatic; immunosuppressive;

Homo sapiens.

WO200055173-A1

21-SEP-2000

08-MAR-2000; 2000WO-US005881

12-MAR-1999; 99US-0124270P.

(HUMA-) HUMAN GENOME SCI INC.

Rosen Ç Ruben SM;

N-PSDB; 2000-611515/58. AAF21871.

New human breast and ovarian cancer associated gene sequences and the polypeptides encoded by these genes, useful in the prevention, treatme and diagnosis of cancer, immune disorders, cardiovascular disorders are neurological diseases. disorders and treatment

Claim 11; Page 1126-1128; 1299pp; English.

Sequences AAF21614 - AAF22031 represent DNA sequences encoding human proteins AAB58711 - AAB59128. The DNA and protein sequences are associated with breast and ovarian cancer. Included in the invention invention are

ヒャルゆけて

```
ecc sequences AAF22032 - AAF22040 and AAB59129 which are used in the ci solation and characterisation of the DNA and protein sequences of the CC invention. The breast and ovarian cancer associated DNA, protein, agonist or antagonist sequences exhibit cytostatic; immunosuppressive; nootropic; antiinflammatory; antiviral; antiallergic; hepatotropic; antibacterial; cc antifungal; antiparasitic and cardiant activity. The polymucleotide and cc protein sequences are used in the diagnosis of cancer, particularly cc and agonists may also be used in the diagnosis of cancer, particularly cc and agonists may also be used in the diagnosis, prevention and treatment of immune disorders e.g. Addison's disease, allergies, autoimmune cd isease, multiple sclerosis, rheumatoid arthritis and ulcerative colitis; cardiovascular diseases such as myocardial ischaemias; wound healing; infertious disease such as cerebral anoxia and epilepsy; and
```

```
片
                 S
                                                          Matches
                                      Query Match
Best Local
                                                          Sequence 465
      158
                              52;
                                     Similarity
        GVKETPOOKYORLLHEVOELTTEVEKIKTTVKESATEEKLTPVLLAKOLAAL 52
GVKETPQQKYQRLLHEVQELTTEVEKIKTTVKESATEEKLTPVLLAKQLAAL 209
                              Conservative
                                                        AA;
                                 100.0%; Score 251; DB 3; 100.0%; Pred. No. 9.4e-21;
                              0
                             Mismatches
                            0,
                                        Length 465;
                           0;
                          Gaps
                          0
```

ABP53019 standard; protein;

ABP53019;

05-NOV-2002 (first entry)

Mouse p50 amino acid sequence SEQ ID NO:54.

RESULT 6
ABP5301.9
ID ABP5
XX ABP5
XX ABP5
XX ABP5
XX MOUB
XX MOUB
XX P50
XX Barc
XX P50
XX Stroo
XX Inmu
XX Cellular proliferation inhibition; cytostatic; antiinflammatory; cancer; p50 inhibitor; dynamitin inhibitor; gene therapy; tumour; carcinoma; sarcoma; glioblatoma; leukaemia; lymphoid malignancy; neuronal disorder; glial disorder; astrocytal disorder; hypothalamic disorder; inflammatory; glandular disorder; macrophagal disorder; epithelial disorder; stromal disorder; blastocoelic disorder; angiogenic disorder; **Emmunologic disorder**

musculus.

WO200264779-A2

22-AUG-2002

21-JAN-2002; 2002WO-US001708.

14-FEB-2001; 2001US-00782816

(REGC) UNIV CALIFORNIA.

Sharp DJ, Rogers GC, Scholey JM;

WPI; 2002-657599/70.

New peptide inhibitors of p50/dynamitin useful for treating cancer by inhibiting cellular proliferation, e.g. benign or malignant tumors, leukemia and lymphoid malignancies, or inflammatory, angiogenic and immunologic disorders.

Disclosure; Fig 2; 55pp; English

present invention describes an isolated peptide (I) comprising or name of the comprision of the compri are the

```
និនិនិនិនិនិនិនិនិនិនិន្និន្និ
                                           and can be used as p50/dynamitin inhibitors and in gene therapy. The peptides, nucleic acid molecules and methods from the present invention are useful for treating cancer by inhibiting cellular proliferation, such as benign or malignant tumours (renal, liver, kidney, bladder, breast, thyroid, hepatic carcinomas, sarcomas, glioblatomas, and various head and neck tumours); leukaemias and lymphoid malignancies, other disorders such as neuronal, glial, astrocytal, hypothalamic and other glandular, inflammatory, angiogenic and immunologic disorders. The present sequence represents mouse p50 which is given in the exemplification of the present
```

Sequence 183 ₽

```
Matches
                           Query Match
                Local
      l Similarity
51; Conserv
      Conservative
               98.8%;
98.1%;
   Score 248; DB 5;
Pred. No. 7.1e-21;
1; Mismatches 0
                       Length 183
   Indels
  <u>,</u>
0
```

밁 ş 94 GVKETPQOKYORLLHEVOELTTEVEKIKTTVKESATEEKLTPVVLAKOLAAL 145 1 GVKETPQQKYQRLLHEVQELTTEVEKIKTTVKESATEEKLTPVLLAKQLAAL 52

ABP53016 standard; peptide; 52 B

ABP53016;

05-NOV-2002 (first entry)

Cellular proliferation peptide inhibitor SEQ ID NO:51.

RESULT 7
ABP5301.6
ID ABP5
XX ABP5
XX ABP5
XX OS-N
XX Cell
XX Cell
XX Ell
XX El Cellular proliferation inhibition; cytostatic; antilnflammatory; cancer; p50 inhibitor; dynamitin inhibitor; gene therapy; tumour; carcinoma; sarcoma; glioblatoma; leukaemia; lymphoid malignancy; neuronal disorder; glial disorder; astrocytal disorder; hymphotalamic disorder; inflammatory; glandular disorder; macrophagal disorder; epithelial disorder; stromal disorder; blastocoelic disorder; angiogenic disorder; mmunologic disorder. disorder; angiogenic disorder;

Homo sapiens.

Mus musculus.

Synthetic

Misc-difference Location/Qualifiers

44 'label= Leu, Val

note= "Leu in humans and Val in Mus musculus"

WO200264779-A2

22-AUG-2002.

21-JAN-2002; 2002WO-US001708

14-FEB-2001; 2001US-00782816

(REGC) UNIV CALIFORNIA

Sharp DJ, Rogers GC, Scholey JM;

WPI; 2002-657599/70.

New peptide inhibitors of p50/dynamitin useful for treating cancer by inhibiting cellular proliferation, e.g. benign or malignant tumors, leukemia and lymphoid malignancies, or inflammatory, angiogenic and immunologic disorders.

Claim 2; Page 31; 55pp; English

The present invention describes an isolated peptide (I) comprising